Post on 20-Jul-2020
ZENTIVA A SANOFI COMPANY Corporate Presentation
ZENTIVA: OUR MISSION
Zentiva mission is to increase the availability of modern high quality affordable generic medicines to more patients
W E A I M T O B E YO U R V A L U E D G E N E R I C S P A R T N E R
OUR MARKET POSITION ZENTIVA IS THE 3rd BIGGEST Gx PLAYER IN ITS TERRITORIES
1.204
2.507
2.433
MYLAN 1.147
BIOGARAN/EGIS 972
STADA 963
KRKA 527
GEDEON RICHTER 404
MENARINI 362
ACTAVIS 358
TEVA
SANDOZ
ZENTIVA
1
2
3
4
5
6
7
8
9
10
in Bn EURO, 2011
OUR MARKETS WE HAVE A WIDE GEOGRAPHICAL COVERAGE ACROSS EUROPE WITH GLOBAL PERSPECTIVES
Zentiva • Operates in more than 35 markets
across Europe and beyond.
• Employs around 3,000 employees in its commercial operations.
• Industrial affairs add another 3,000 employees to the Zentiva community.
• Reaches out to a target population of over 800 million patients.
• Prague headquarters is the decision making centre for strategy and global R&D for Sanofi Gx business worldwide.
OUR ORIGINS Z E N T I V A H A S A L O N G H I S T O R Y O F P R O D U C I N G
H I G H Q U A L I T Y P H A R M A C E U T I C A L S
1488 1930 1998 2000 2003 2004 2005 2007 2009 2011 2012
Zentiva traces its origins back to the “At the Black Eagle” Pharmacy in Prague
Zentiva listed on the Prague and London Stock Exchanges
Zentiva acquired Eczacibaci Generic Pharmaceuticals, a leading pharmaceutical company in Turkey
Management buyout
Acquisition of Slovakofarma + Launch of the Zentiva corporate brand
Zentiva acquired Sicomed, the leading generics company in Romania
Zentiva recognized
as Generics Business of Sanofi Group
Manufacturing beings at Prague site
Business
Rationalisation
Positioned for Regional Growth
Leading CEE Player Expanding Internationally
Zentiva combined with Sanofi
Zentiva entered Western Europe through rebranding of Winthrop and Helvepharm
Zentiva leads global Sanofi‘s Gx portfolio strategy and development
OUR THERAPEUTIC AREAS
C A R D I O V A S C U L A R
F E M A L E H E A L T H C A R E
R E S P I R A T O R Y
A N T I - I N F E C T I V E S & A N T I - F U N G A L S
U R O L O G Y
C N S
P A I N
G A S T R O I N T E S T I N A L
OUR INDUSTRIAL AFFAIRS WE ARE ONE OF LARGEST PRODUCERS OF AFFORDABLE MEDICINES BASED IN EUROPE EMPLOYING AROUND 3,000 PEOPLE WITH A TOTAL PRODUCTION OF ALMOST 450M PACKS
TR / Lüleburgaz DP Development and Production
DE / Munich Respiratory Development
CZ / Prague API and DP Development, Pharma Production
SK / Hlohovec API and Pharma Production, DP Development
RO / Bucharest Pharma Production
DP: drug product | API: Active pharmaceutical ingredient
Munich
Prague
Hlohovec
Bucharest
Lüleburgaz
HC: 808 people
HC: 882 people
HC: 399 people
HC: 816 people
HC: 72 people
OUR RESPONSIBILITY ZENTIVA SUSTAINABILITY APPROACH PLACES THE PATIENT AT THE HEART OF ITS BUSINESS CONDUCT. THIS APPROACH IS BASED ON FOUR KEY AREAS:
PAT I E N T
P E O P L E
E T H I C S
P L A N E T
Zent iva Group a .s .
U Kabe lovny 130 / / 102 37 Prague 10 / / Czech Repub l i c
Phone : (+420) 267 241 111 / / E -ma i l : zen t i va@zent i va .com
www.zent iva .com
WE ARE
ZENTIVA